Literature DB >> 10890359

HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe.

M Batra1, P C Tien, R W Shafer, C H Contag, D A Katzenstein.   

Abstract

HIV-1 envelope sequence patterns have implications for virus cell tropism and for the development of an effective vaccine. To identify the sequence characteristics of recently transmitted HIV-1 isolates in southern Africa, we sequenced the V3-V5 envelope regions of 24 male seroconverters in Harare, Zimbabwe. Each of the sequences clustered with previously reported subtype C isolates and there was a mean 17% intersequence pairwise genetic distance between the Zimbabwean isolates. Three isolates were syncytium inducing (SI). One of the SI isolates had an unusual GIGK crown and a deletion at codon 23; one had the codon 23 deletion alone; and one had a high net positive charge in the V3 loop. The extensive genetic diversity within the envelope of subtype C HIV-1 isolates must be considered in vaccine development. Further analysis of subtype C SI isolates and site-directed mutagenesis experiments are required to determine the molecular basis of SI activity in global HIV-1 isolates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890359     DOI: 10.1089/08892220050058399

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.

Authors:  Mia Coetzer; Rebecca Nedellec; Tonie Cilliers; Tammy Meyers; Lynn Morris; Donald E Mosier
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

2.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

3.  Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5).

Authors:  Elizabeth Johnston White; Bryan McColgan; Seble Kassaye; Lynn Zijenah; David Katzenstein
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

4.  Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe.

Authors:  Sudeb C Dalai; Tulio de Oliveira; Gordon W Harkins; Seble G Kassaye; Jennifer Lint; Justen Manasa; Elizabeth Johnston; David Katzenstein
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

5.  CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells.

Authors:  Grant R Campbell; Stephen A Spector
Journal:  J Biol Chem       Date:  2008-09-10       Impact factor: 5.157

6.  Appreciating HIV type 1 diversity: subtype differences in Env.

Authors:  Rebecca M Lynch; Tongye Shen; S Gnanakaran; Cynthia A Derdeyn
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

7.  Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C.

Authors:  Nina H Lin; Carlos Becerril; Francoise Giguel; Vladimir Novitsky; Sikhulile Moyo; Joseph Makhema; Myron Essex; Shahin Lockman; Daniel R Kuritzkes; Manish Sagar
Journal:  Virology       Date:  2012-09-03       Impact factor: 3.616

Review 8.  Evolution and diversity of HIV-1 in Africa--a review.

Authors:  Maria A Papathanasopoulos; Gillian M Hunt; Caroline T Tiemessen
Journal:  Virus Genes       Date:  2003       Impact factor: 2.332

Review 9.  Clinical significance of HIV-1 coreceptor usage.

Authors:  Hanneke Schuitemaker; Angélique B van 't Wout; Paolo Lusso
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

10.  HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].

Authors:  Martin Mulinge; Morgane Lemaire; Jean-Yves Servais; Arkadiusz Rybicki; Daniel Struck; Eveline Santos da Silva; Chris Verhofstede; Yolanda Lie; Carole Seguin-Devaux; Jean-Claude Schmit; Danielle Perez Bercoff
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.